Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial
Authors
Keywords
-
Journal
OncoImmunology
Volume -, Issue -, Pages 1-13
Publisher
Informa UK Limited
Online
2019-05-25
DOI
10.1080/2162402x.2019.1614857
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Intratumoral CD56bright natural killer cells are associated with improved survival in bladder cancer
- (2018) Neelam Mukherjee et al. Oncotarget
- Immune-Stimulatory Effects of Rapamycin Are Mediated by Stimulation of Antitumor T Cells
- (2016) V. Dao et al. CANCER RESEARCH
- BCG Vaccination Induces Robust CD4+T Cell Responses toMycobacterium tuberculosisComplex–Specific Lipopeptides in Guinea Pigs
- (2016) Eva Kaufmann et al. JOURNAL OF IMMUNOLOGY
- Tuberculosis Infection in the United States: Prevalence Estimates from the National Health and Nutrition Examination Survey, 2011-2012
- (2015) Roque Miramontes et al. PLoS One
- Activating and Propagating Polyclonal Gamma Delta T Cells with Broad Specificity for Malignancies
- (2014) D. C. Deniger et al. CLINICAL CANCER RESEARCH
- Sequential Intravesical Mitomycin plus Bacillus Calmette-Guerin for Non-Muscle-Invasive Urothelial Bladder Carcinoma: Translational and Phase I Clinical Trial
- (2014) R. S. Svatek et al. CLINICAL CANCER RESEARCH
- Advances in NKG2D ligand recognition and responses by NK cells
- (2014) Nina Le Bert et al. IMMUNOLOGY AND CELL BIOLOGY
- Bacillus Calmette-Guérin immunotherapy for genitourinary cancer
- (2013) Nilay M. Gandhi et al. BJU INTERNATIONAL
- Antigen-Specific CD4 T Cells Are Induced after Intravesical BCG-Instillation Therapy in Patients with Bladder Cancer and Show Similar Cytokine Profiles as in Active Tuberculosis
- (2013) Julia Elsäßer et al. PLoS One
- Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance
- (2012) Jorg Oddens et al. EUROPEAN UROLOGY
- Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer
- (2012) C. Biot et al. Science Translational Medicine
- Human T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement
- (2010) A. Maniar et al. BLOOD
- IL-17 production by γδ T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guérin treatment against bladder cancer
- (2010) Ario Takeuchi et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Bacillus Calmette-Guérin Is Superior to a Combination of Epirubicin and Interferon-α2b in the Intravesical Treatment of Patients with Stage T1 Urinary Bladder Cancer. A Prospective, Randomized, Nordic Study
- (2009) Miloš Duchek et al. EUROPEAN UROLOGY
- Molecular Analyte Profiling of the Early Events and Tissue Conditioning Following Intravesical Bacillus Calmette-Guerin Therapy in Patients With Superficial Bladder Cancer
- (2009) Aurélie Bisiaux et al. JOURNAL OF UROLOGY
- A New Recombinant Bacille Calmette‐Guérin Vaccine Safely Induces Significantly Enhanced Tuberculosis‐Specific Immunity in Human Volunteers
- (2008) Daniel F. Hoft et al. JOURNAL OF INFECTIOUS DISEASES
- The Tuberculin Skin Test Increases the Responses Measured by T Cell Interferon-Gamma Release Assays
- (2008) C. Vilaplana et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started